Filing Flows › Health Care › Bio Essence (BIOE)
Bio Essence (BIOE) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Bio Essence (BIOE) Q2 2026 earnings results →
Q2 2026 Revenue up 207% year over year to $795K · 34¢ of every $1 of revenue kept as net profit · operating margin 35.1%
Bio Essence made $795K in Q2 2026 (+207% Y/Y). Operating margin 35.1%, net earnings $270K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $795K in Q2 2026, up 207% year over year and up 59% from the previous quarter.
Gross margin was 59.2%, down 5.9 points from Q2 2025. Operating profit was $279K, a 35.1% margin (up 11.5 points year over year). Of the extra revenue versus Q2 2025, 41% reached operating profit, above the 24% margin then. Operating expenses grew 78% against revenue growth of 207%. Net earnings were $270K, up 351% year over year. The effective tax rate was 3.7%.
Operating cash flow was $60K (down 64% year over year), 22% of net earnings. Non-cash charges added back $104K of depreciation and amortization. Working capital and other items used $314K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $795K | +207% | 35.1% | $270K | $60K |
| Q1 2026 | 10-Q | May 15, 2026 | $501K | 23× | 43.1% | $205K | −$412K |
| Q4 2025 | 10-K | Mar 27, 2026 | $1.5M | +903% | 69.6% | $1.0M | $1.2M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $137K | +2% | 10.4% | $13K | $187K |
| Q2 2025 | 10-Q | Aug 14, 2025 | $259K | +522% | 23.6% | $60K | $168K |
| Q1 2025 | 10-Q | May 15, 2025 | $22K | — | -924.3% | −$206K | −$26K |
| Q4 2024 | 10-K | Mar 28, 2025 | $148K | — | 2.6% | −$28K | $423K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Bio Essence
Bio Essence Corp. (“we,” “us,” “Bio Essence,” or the “Company”) is an herbal health, diet, and nutrition company. The Company’s mission is to provide herbal health, diet, and vitamin nutritional supplements, as explained below. The Company was incorporated in the State of California on January 1, 2000. On January 27, 2016, the Company entered into a change of control whereby our controlling shareholder, Jian Yang, purchased a controlling interest in the Company. On that same date, Jian Yang entered into a stock purchase agreement with Fusion Diet Systems, Inc. a Utah corporation dba, Fusion Naturals (“Fusion Naturals”). Fusion Naturals was originally incorporated in Utah on April 20, 2010. On January 9, 2017, the Company created a new corporation in the State of California called Bio Essence Pharmaceutical, Inc. to serve as a health supplements manufacturer (“BEP”).
In its own words, from its 10-K, filed Mar 27, 2026.
Bio Essence against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +207% against the peers' median +10%. Operating margin: 35.1% against the peers' median 30.7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BIOE Bio Essence | Q2 2026 | $795K | +207% | 35.1% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Bio Essence 10-Q on SEC EDGAR · CIK 1723059 · Pharmaceutical Preparations
More on BIOE
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results